Drugs Policy In Francophone Africa

16 January 1995

The devaluation of the French franc at the start of 1994 and its consequences for the accessibility of drugs and therapeutic quality in French-speaking Africa is a major concern of the pharmaceutical industry in France, and was discussed at a conference organized by the French drug industry association SNIP, in April 1994.

Papers presented at the conference and the ensuing debates are now available in book form. They include: new conditions of access to drugs after the devaluation; the European Development Fund medicines policy; and the setting up and management of "social" drug lists. For further details and to obtain a copy, priced 165 francs (plus 20 francs p&p) contact: SEFEFIM, 25 rue de Montevideo, 75015 Paris, France.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight